Back to trial details

Intake questionnaire

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Applying to NEXT Houston · Houston, Texas

Answer a few short questions to share with the research team.

0 of 3 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with EGFR Mutation Positive Non-small Cell Lung Cancer?
3. Are you able to travel to Houston for study visits?